More than 9,000 people live with MS in Ireland, and significantly more women than men are diagnosed with MS
Neuraxpharm Ireland, part of Neuraxpharm Group, a leading European speciality pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announced the launch of BRIUMVI® (ublituximab) in Ireland for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease.1
BRIUMVI® is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of RMS.
BRIUMVI® is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion.2
In clinical studies, patients who received BRIUMVI® had a median B -cell depletion of 97 per cent 24 hours after the first dose.1
BRIUMVI®is administered as a one-hour infusion twice per year following an initial dose (administered over four hours), thereby limiting the time spent in the infusion suite for the patient and reducing the burden on the healthcare provider.1
More than 9,000 people live with MS in Ireland, and significantly more women than men are diagnosed with MS. Around 85 per cent of all people with MS are diagnosed with RMS.3
Rose Brady, Country Manager, Neuraxpharm Ireland, said: “We are delighted to make BRIUMVI® available to MS patients and Healthcare providers in Ireland. The launch of BRIUMVI® is an important milestone for Neuraxpharm and demonstrates our commitment to bring innovative treatments to patients with Multiple Sclerosis in Ireland.”
References:
- BRIUMVI® Summary of Product Characteristics available at www.medicines.ie
- Steinman L et al Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis N Engl J Med 2022:387;8.704-714
- Multiple Sclerosis The Facts: MS Society of Ireland available at Multiple Sclerosis: The Facts | MS Ireland
IEBRI/12/2024/009